Speaking during ministerial questions yesterday, Parliamentary under secretary for state for health and social care, James Frith, said the current contract must ‘remain stable while the future model is designed and procured'.
The Government has come under increasing pressure to end the Palantir contract due to the company's contracts with Israel's military and US Immigration and Customs Enforcement.
Welcoming the announcement, Helen Morgan, Lib Dem health and social care spokesperson, said: ‘A Trump-aligned tech giant should be nowhere near the data of millions of NHS patients and a piece of important national infrastructure.'
Morgan added: ‘The reality is that over the next two years this platform will become a lame duck, and we need to use that time to best effect.'
Martin Wrigley, Liberal Democrat MP for Newton Abbot, said: ‘Patients and doctors deserve better. The Government must speed up this retender, make sure Palantir can't slip back in through the "next generation" FDP, and finally put trusted British suppliers first.'
The FDP is live in 142 NHS trusts and 35 integrated care boards and supports operational services, including vaccine supply chains, theatre scheduling and discharge planning.
Deputy chief executive of The NHS Alliance, Sarah Walter, said: ‘The forthcoming procurement offers an opportunity to reset and clarify the purpose, vision and capabilities of the FDP around clearly defined clinical and operational goals. A new FDP must restore meaningful local choice, show independently assessed benefits, and be open and transparent in how suppliers and FDP products are chosen to avoid vendor lock in. A future FDP model must be co-designed with NHS leaders and frontline workforce so that more meaningful FDP is developed and implemented.'
Tom Watson, senior vice president, Palantir UK, said: ‘This is good news for patients and for the NHS.'
Watson said ministers had acknowledged the programme was ‘significantly exceeding its benefits forecast and has exceeded every target' since it launched in 2024'.
Watson said Palantir had helped ‘deliver more operations, speed up discharge and reduce the time patients need to wait to find out if they have cancer'.
Concerns over NHS England's presentation of FDP-related data about patient removals from waiting lists are being examined by the Office for Statistics Regulation (OSR) after they were contested.
